Ocumension Therapeutics (OCUT.F) Stock Overview

Engages in the research, discovery, development, and commercialization of ophthalmic therapies in China. More details

OCUT.F fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 53.3% below our estimate of its fair value

Earnings are forecast to grow 94.61% per year

Earnings have grown 39.1% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

OCUT.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW480,107 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

480,107 investors already sharing narratives

View all narratives

Ocumension Therapeutics Competitors

Price History & Performance

Summary of share price highs, lows and changes for Ocumension Therapeutics
Historical stock prices
Current Share Price	HK$0.70
52 Week High	HK$0.70
52 Week Low	HK$0.70
Beta	0.40
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	OCUT.F	US Pharmaceuticals	US Market
7D	0%	1.6%	-1.4%
1Y	n/a	40.1%	16.4%

Return vs Industry: Insufficient data to determine how OCUT.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how OCUT.F performed against the US Market.

Price Volatility

Is OCUT.F's price volatile compared to industry and market?
OCUT.F volatility
OCUT.F Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	9.1%
Market Average Movement	7.1%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.2%

Stable Share Price: OCUT.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine OCUT.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2017	552	Victor Liu	www.ocumension.com

Ocumension Therapeutics, together with its subsidiaries, engages in the research, discovery, development, and commercialization of ophthalmic therapies in China. The company offers various ophthalmic drugs for the treatment of chronic non-infectious uveitis, wet age-related macular degeneration, diabetic macular edema, choroidal neovascularization, dry eye disease, glaucoma, allergic and bacterial conjunctivitis, fungus disease, and anti-inflammatory, as well as postoperative ocular inflammation, paralysis of ciliary muscle, and pupil dilation, as well as eyelid and periocular cleansing. It also develops drugs in Phase III clinical trial, including OT-101 for myopia, OT-802 for presbyopia, OT-211 for dry eye disease, and OT-301 for glaucoma; and drugs in Phase I/II clinical trial, such as OT-703 for diabetic macular edema, OT-202 for dry eye disease, and OT-601-C for the treatment of ocular inflammation.

Ocumension Therapeutics Fundamentals Summary

How do Ocumension Therapeutics's earnings and revenue compare to its market cap?
OCUT.F fundamental statistics
Market cap	US$592.71m
Earnings (TTM)	-US$23.45m
Revenue (TTM)	US$118.77m

5.0x

P/S Ratio

-25.3x

P/E Ratio

Is OCUT.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OCUT.F income statement (TTM)
Revenue	CN¥804.35m
Cost of Revenue	CN¥443.43m
Gross Profit	CN¥360.92m
Other Expenses	CN¥519.74m
Earnings	-CN¥158.82m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.19
Gross Margin	44.87%
Net Profit Margin	-19.75%
Debt/Equity Ratio	4.3%

How did OCUT.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/23 00:19
End of Day Share Price	2026/06/08 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ocumension Therapeutics is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yanyin Zhu	China International Capital Corporation Limited
Fang Quan	China International Capital Corporation Limited
Ziyi Chen	Goldman Sachs

Ocumension TherapeuticsOTCPK:OCUT.F Stock Report